| Not Yet Recruiting | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers NCT05108870 | University of Chicago | Phase 1 / Phase 2 |
| Not Yet Recruiting | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma NCT07497607 | Sara Medek | Phase 2 |
| Not Yet Recruiting | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReAC NCT07513324 | Dana-Farber Cancer Institute | Phase 2 |
| Not Yet Recruiting | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs NCT07418034 | University of Maryland, Baltimore | Phase 2 |
| Not Yet Recruiting | CUE-101with Pembrolizumab for LA-HPV+HNSCCs NCT07172256 | Yale University | Phase 2 |
| Recruiting | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers NCT05639972 | Christian Hinrichs | Phase 1 / Phase 2 |
| Recruiting | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Canc NCT07063212 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinom NCT06790966 | PDS Biotechnology Corp. | Phase 3 |
| Recruiting | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) NCT06307015 | Royal North Shore Hospital | N/A |
| Not Yet Recruiting | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC. NCT06797986 | Cellid Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Surgery and Reducing Ionizing Radiation of the Unknown Primary NCT06578871 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Recruiting | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer NCT06319963 | Theravectys S.A. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) NCT05973487 | TScan Therapeutics, Inc. | Phase 1 |
| Recruiting | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SA NCT06088381 | University of Maryland, Baltimore | Phase 2 |
| Recruiting | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma NCT06016920 | Nykode Therapeutics ASA | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) NCT05814549 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers NCT05686226 | Christian Hinrichs | Phase 2 |
| Completed | The SPOT-HPV Study NCT05524025 | Dana-Farber Cancer Institute | — |
| Recruiting | De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx NCT05600842 | University of California, Irvine | — |
| Recruiting | The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) NCT05419089 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Active Not Recruiting | Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell C NCT05119036 | Indiana University | N/A |
| Recruiting | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With H NCT05307939 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Stud NCT04900623 | Jonathan Schoenfeld, MD, MPH | Phase 2 |
| Terminated | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Sele NCT05061940 | Repertoire Immune Medicines | — |
| Completed | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC NCT04260126 | PDS Biotechnology Corp. | Phase 2 |
| Completed | Improving Detection and Early Action for HPV-positive Oropharynx Cancer NCT04871490 | Brigham and Women's Hospital | N/A |
| Active Not Recruiting | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV NCT04255849 | Weill Medical College of Cornell University | Phase 3 |
| Active Not Recruiting | Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal NCT04502407 | Cedars-Sinai Medical Center | Phase 2 |
| Recruiting | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal NCT04444869 | University of Missouri-Columbia | Phase 2 |
| Completed | ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPV NCT06730412 | Massachusetts Eye and Ear Infirmary | — |
| Terminated | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors NCT04301011 | Turnstone Biologics, Corp. | Phase 1 |
| Withdrawn | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients NCT04001413 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma NCT03978689 | Cue Biopharma | Phase 1 |
| Withdrawn | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Unde NCT03611205 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer NCT03601507 | University of Arizona | Phase 2 |
| Recruiting | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma NCT03215719 | NYU Langone Health | Phase 2 |
| Completed | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and NCT02113878 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer NCT02002182 | Andrew Sikora | Phase 2 |
| Unknown | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma NCT01855451 | Trans Tasman Radiation Oncology Group | Phase 3 |